Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial - Concepedia

Concepedia

Publication | Open Access

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

DOI Full Paper Access

636

Citations

27

References

2015

Year

Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel, Gregory J. Riely, Jeremy Cetnar, Howard West, D. Ross Camidge, Mark A. Socinski, Alberto Chiappori, Tarek Mekhail,

The Lancet Oncology

Non-small-cell Lung CancerMedicinePathologyBronchial NeoplasmCancer TreatmentPhase 2OncologyRadiation OncologyLung CancerCancer Growth

References

	Year	Citations

Page 1

Page 1